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We examined prospectively the relation between regular aspirin use and lung cancer risk in the Health Professionals Follow-Up
Study. Of 49383 US men aged 40–75 years who completed biennial self-administered questionnaires that assessed aspirin use
beginning in 1986, 328 developed lung cancer during 601453 person-years of follow-up through 31 December 2000. No
information on aspirin dose was available. Controlling for current age, smoking status, and age at starting to smoke regularly, the
relative risk (RR) of total lung cancer for regular users of aspirin (twice or more per week) at baseline compared to nonusers was 1.13
(95% confidence interval (CI) ¼0.89–1.43). Results were similar for non-small-cell lung cancer (RR¼1.16; 95% CI¼0.88–1.54). No
apparent dose-dependent association was observed for the frequency of aspirin use and lung cancer risk (P for trend¼0.64), and
results remained null when consistent use of aspirin over time was examined. These findings do not suggest that regular aspirin use is
associated with a reduced lung cancer risk.
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Evidence from animal studies suggests that aspirin and possibly
other nonsteroidal anti-inflammatory drugs (NSAIDs) including
cyclooxygenase-2 (COX-2) inhibitors may influence the develop-
ment and progression of lung cancer (Duperron and Castonguay,
1997; Rioux and Castonguay, 1998; Yao et al, 2000). As COX-2
enzymes are constitutively expressed in lung neoplastic tissue (Xu,
2002), reduced synthesis of prostaglandins from arachidonic acid
by inhibition of COX-2 enzymes may have preventive or
therapeutic effects in lung carcinogenesis.
Clinical and epidemiological studies, however, have not
consistently supported for the hypothesis that regular use of
aspirin and other NSAIDs reduces lung cancer incidence but are
limited in several key areas. These include residual confounding
due to broad categories of smoking habits (Paganini-Hill et al,
1989; Schreinemachers and Everson, 1994; Langman et al, 2000;
Akhmedkhanov et al, 2002; Moysich et al, 2002); misclassification
due to a single assessment of aspirin use (Paganini-Hill et al, 1989;
Schreinemachers and Everson, 1994; Harris et al., 2002); and small
number of lung cancer cases observed (Peto et al, 1988; Paganini-
Hill et al, 1989; Schreinemachers and Everson, 1994; Akhmedkha-
nov et al, 2002).
Given the limitations of previous literature and uncertainty
regarding the protection of aspirin against lung cancer risk, we
examined the association between regular use of aspirin and lung
cancer incidence in a large cohort of US. male health professionals
with long-term aspirin use and detailed information on smoking
history.
MATERIALS AND METHODS
Study population
The Health Professionals Follow-Up Study (HPFS) is an ongoing
prospective cohort study of 51529 US male dentists, optometrists,
osteopaths, podiatrists, pharmacists, and veterinarians aged 40–75
years. The primary objective of the study is to evaluate a series of
hypotheses relating nutritional and lifestyle factors to the
incidence of cancer, heart disease, and other major diseases. At
baseline in 1986, enrollees returned a mailed questionnaire that
assessed information on lifestyle factors, aspirin and other NSAID
use, diet, and medical and smoking histories. Follow-up ques-
tionnaires are mailed biennially to the entire cohort to update
information on potential risk factors and ascertain new cases of
disease.
Assessment of aspirin use
Regular use of aspirin (e.g. Anacin, Bufferin, Alka-Seltzer),
acetaminophen (e.g. Tylenol), and other NSAIDs (e.g. Motrin,
Indocin, Naprosyn, Dolobid) separately defined as two or more
times per week was ascertained in 1986 and updated every 2 years
thereafter. More detailed questions on aspirin use began in the
1992 questionnaire. Frequency of aspirin use was assessed by the
average number of days each month aspirin was taken (none, 1–4,
5–14, 15–21, or 22 or more). Information on aspirin dose was not
available.
Reasons for aspirin use were assessed in 1993 by a supplemen-
tary questionnaire sent to a random sample of 211 participants,
who reported taking aspirin from 1986 to 1990. Of the 211 men,
185 (88%) responded and reported one or more of the following
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yreasons: cardiovascular disease, 25%; to decrease risk for
cardiovascular disease, 58%; headache, 25%; joint or musculoske-
letal pain, 33%; and other or unknown reasons, 7%. We were
unable to examine long-term use of acetaminophen and other
NSAIDs separately because of the small number of men who used
them regularly (approximately 6% of the cohort).
Identification of lung cancer cases
On each biennial questionnaire participants were asked whether
they had been diagnosed with lung cancer during the previous 2
years. The follow-up rate with respect to the incidence of cancer
was 96% of the total possible person-years. After receiving
permission from identified cases (or next of kin for decedents),
hospital records and pathology reports were obtained and
reviewed by a physician for histological confirmation. Information
on lung cancer cell type was available for approximately 80%.
Deaths in the cohort were ascertained through family members
and the National Death Index (Stampfer et al, 1984). Cases
diagnosed between date of 1986 questionnaire return and 31
December 2000 were included in this report (n¼328).
Statistical analysis
Follow-up for each participant was calculated from the date of
return of the 1986 questionnaire until the date of lung cancer
diagnosis, date of death from any cause, or 31 December 2000,
which ever came first. At baseline in 1986, we excluded 2069 men
who reported a history of cancer other than nonmelanoma skin
cancer by 1986, 40 men who incorrectly completed the ques-
tionnaire, and 37 men who later wished to be removed from the
cohort. Only those with complete information on aspirin use at
baseline were included in the analyses. The analytic cohort
consisted of 49383 men representing 601453 person-years of
follow-up. Cox proportional hazards models were used to estimate
relative risks (RRs) and 95% confidence intervals (CI).
To take account for changes in aspirin use over time and best
represent long-term use of aspirin, our analyses were conducted
using consistent aspirin use. For example, lung cancer from 1986
through 2000 was related to aspirin use reported on the 1986
questionnaire, that from 1988 through 2000 to consistent use
reported in the 1986 and 1988 questionnaires, that from 1990
through 2000 use reported on the 1986, 1988, and 1990
questionnaires, and that from 1992 through 2000 use reported
on the 1986, 1988, 1990, and 1992 questionnaires. Consistent
aspirin users were compared to nonusers (i.e., participants who
consistently reported no aspirin use during the same specified time
periods).
Potential confounders were specified a priori based on a review
of putative risk factors for lung cancer and included age (year);
marital status; body mass index (kgm
 2); use of multivitamins,
vitamin A, vitamin C, vitamin E, b-carotene, and selenium
supplements (yes or no); intake of fruit and vegetables; energy-
adjusted a-carotene, b-carotene, lycopene, lutein/zeaxanthin, and
b-cryptoxanthin; alcohol use; and family history of lung cancer.
Smoking history was categorised as the combination of age at
starting to smoke regularly (less than 15, 15–19, 20–29, and more
than 30 years old) and smoking status, which included current
smoking (1–4, 5–14, 15–24, 25–34, 35–44, and 45 or more
cigarettes per day), past smoking with time since quitting (less
than 10 years and 10 or more years), and never smoked.
Multivariate models included current age, age at starting to smoke
regularly, and smoking status (included time since quitting and
dose), plus the additional confounders mentioned previously that
were assessed by evaluating whether their inclusion into the
multivariate model changed the risk estimate by more than 10%.
Additional analyses were restricted to non-small-cell lung cancer
(NSCLC) (squamous carcinoma, adenocarcinoma, and large cell
carcinoma). Potential interaction by smoking status category
(never, past, and current separately) and baseline aspirin use was
assessed using a cross-product term in multivariate models. Tests
of linear trends for increasing categories of aspirin use were
conducted by assigning the median value of aspirin use for
categories and treating these as a single continuous variable.
Reported P-values are based on two-sided tests.
RESULTS
At baseline in 1986, about one-third of men reported regular
aspirin use defined as two or more tablets per week (Table 1).
Aspirin users tended to be slightly older, to have smoked, and to
have started smoking at an earlier age. Dietary patterns were very
Table 1 Characteristics
a (means and proportions) of the HPFS cohort
by aspirin use at baseline in 1986
Aspirin
Characteristic Nonuse Use
b
Participants (n) 34841 14542
Age (years) 53.7 56.4
Height (in) 70.0 70.1
Body mass index (kgm
 2) 24.9 25.1
Smoking history
c
Smoking status (%)
Never 45.8 41.9
Past (years)
o10 11.4 14.9
10+ 27.7 31.9
Current (cigarettes per day)
1–4 0.9 1.1
5–14 1.5 1.9
15–24 3.2 3.1
25–34 1.4 1.6
35–44 1.0 1.2
45+ 0.4 0.5
Age (years) at starting to smoke (%)
o15 5.7 6.9
15–19 18.9 23.4
20–29 20.8 23.6
30+ 47.6 44.0
Years since quitting 8.3 8.1
Intakes (per day)
Fruit and vegetable 5.3 5.3
b-Carotene (mg) 5150 5039
a-Carotene (mg) 949 918
Lycopene (mg) 10374 10321
Multivitamin use (%) 39.4 50.0
Supplement use (per day)
Vitamin C (mg) 57.6 67.7
Vitamin E (IU) 17.6 22.7
Vitamin A (IU) 7.9 9.3
Selenium (mg) 6.2 7.5
b-Carotene
d (mg) 1.9 2.6
Family history of lung cancer (%) 5.7 6.0
Disease history (%)
Asthma 5.2 5.4
Emphysema or chronic bronchitis
e 1.4 1.6
Rheumatoid arthritis 2.0 3.1
Other arthritis (e.g. degenerative) 7.3 12.2
aStandardised to the age distribution of the study population.
bAspirin use was
defined as aspirin use two or more times per week.
cValues do not add up to 100%
because of missing values.
dUse of supplement on a regular basis.
eData from the
1996 follow-up questionnaire.
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the tendency of aspirin users to also take supplements. Family
history of lung cancer was similar among users and nonusers of
aspirin.
Overall, we observed no significant association between aspirin
use at baseline and total lung cancer incidence (Table 2). Age-
adjusted associations were attenuated after adjustment for age at
starting to smoke regularly and smoking status but did not
change appreciably after additional inclusion of the other
covariates. The association between duration of aspirin use and
lung cancer risk became slightly inverse with evidence of more
consistent aspirin use (consecutive RRs of 1.13, 0.98, 0.88, and
0.89), but the results were not statistically significant. After
adjustment for current age, age at starting to smoke regularly,
and smoking status the RR of total lung cancer for users of
acetaminophen and other NSAIDs separately at baseline compared
to nonusers was 1.26 (95% CI¼0.81–1.96) and 1.07 (95%
CI¼0.69–1.66), respectively (N¼23 cases among users for both
compounds).
Previous studies (Akhmedkhanov et al, 2002; Moysich et al,
2002) have examined the association between aspirin use and
NSCLC. We limited the analysis to NSCLC (227 cases) and
compared baseline aspirin use with nonuse of aspirin (Table 2); the
multivariate risk was 1.16 (95% CI¼0.88–1.54). Furthermore, no
evidence of an association was observed with increasing consis-
tency of aspirin use and risk of NSCLC.
We also evaluated the association between frequency of aspirin
use, first assessed in 1992, and lung cancer risk, but no dose-
dependent association was observed. The multivariate RRs of lung
cancer for increasing frequency of aspirin use (0–4, 5–21, and 22
or more days per month) were 1.00, 0.62, and 1.21 (95% CI¼0.68–
2.16), respectively (P for trend¼0.64). Similar nonsignificant
associations for any given amount of aspirin use were observed for
the non-small-cell types (P for trend¼0.40).
No evidence of interaction was observed between categories of
smoking status and baseline aspirin use for lung cancer risk. After
controlling for age, the RR of lung cancer for aspirin users vs
nonusers among never smokers was 1.37 (95% CI¼0.70–2.69);
for past smokers the RR was 1.10 (95% CI¼0.81–1.50), and
for current smokers the RR was 1.27 (95% CI¼0.79, 2.06)
after additional adjustment for age at starting to smoke
regularly. However, the relatively low number of lung cancer cases
within each smoking category (never: 40, past: 179, and current:
104; data missing: five cases) gave limited power to detect
interactions.
DISCUSSION
In this prospective study among male health professionals, twice
or more weekly aspirin use was not associated with risk of total
lung cancer or NSCLC, even for long-term consistent users. Also,
no dose–response association was observed for frequency of
aspirin use and lung cancer incidence.
Several epidemiologic studies have reported an increased
incidence of lung cancer associated with several inflammatory-
related lung diseases including asthma and chronic bronchitis,
suggesting that inflammation may play an important etiologic role
(Wu et al, 1995; Mayne et al, 1999; Brownson and Alavanja, 2000;
Brenner et al, 2001). The reduction of inflammatory prostaglan-
dins by inhibition of COX-2 by NSAIDs, including aspirin, might
have a chemopreventive effect. However, in a recent study of
hydroxytoluene-induced early lung adenocarcinoma in mice,
aspirin attenuated pulmonary inflammation but was ineffective
at preventing lung tumorigenesis (Kisley et al, 2002). In other
animal studies, COX-2 was also consistently expressed in normal
bronchoalveolar and alveolar epithelium of the lung (Bauer et al,
2000; Wardlaw et al, 2000), casting some doubt on a specific role of
COX-2 in the development of lung cancer.
Results from previous clinical and epidemiological studies of
aspirin use and the risk of lung cancer have been mixed. An early
trial among British physicians found a statistically nonsignificant
36% lower mortality rate from lung cancer among users of aspirin
compared to nonusers (Peto et al, 1988). A prospective study based
on data from the National Health and Nutrition Examination
Survey found among men a statistically significant 46% lower lung
cancer risk among users of aspirin during the 30-day period
preceding recruitment into the cohort compared with nonusers
(Schreinemachers and Everson, 1994). Two recent case–control
studies (Harris et al, 2002; Moysich et al, 2002) found statistically
significant reductions in lung cancer risk for aspirin users
compared to nonusers. In contrast, some prospective studies
reported no overall differences in lung cancer mortality (Thun et al,
1993) or incidence (Paganini-Hill et al, 1989) between aspirin users
and nonusers, consistent with our results. Furthermore, in two
case–control studies, lung cancer risk was not significantly lower
for regular aspirin use defined as 4 days per week for 3 months
compared to nonuse (Rosenberg et al, 1991) or seven prescriptions
of aspirin and other NSAIDs received in 13–36 months before
diagnosis compared to no prescriptions (Langman et al, 2000). In a
recent case–control study, a nonsignificant reduction in total lung
cancer risk (odds ratio (OR)¼0.66; 95% CI¼0.34–1.28, adjusted
Table 2 Relative risk of lung cancer by aspirin use in the HPFS, 1986–2000
Aspirin use
a
Variable 1986 1986+1988 1986+1988+1990 1986+1988+1990+1992
Follow-up period
b 1986–2000 1988–2000 1990–2000 1992–2000
Total cases
Nonusers, cases/person-years 204/428 688 96/202 457 66/126 065 22/44 436
Users, cases/person-years 124/172 765 64/93 431 41/52 730 28/37 478
Age-adjusted RR
c (95% CI) 1.19 (0.95–1.49) 1.11 (0.80–1.53) 1.07 (0.72–1.60) 1.18 (0.66–2.10)
Multivariate RR
d (95% CI) 1.13 (0.89–1.43) 0.98 (0.70–1.36) 0.88 (0.58–1.34) 0.89 (0.47–1.67)
Non-small-cell carcinomas
Nonusers, cases/person-years 140/428 717 69/202 466 45/126 073 13/44 441
Users, cases/person-years 87/172 789 49/93 441 33/52 733 24/37 479
Age-adjusted RR
c (95% CI) 1.25 (0.95–1.64) 1.20 (0.82–1.74) 1.27 (0.80–2.01) 1.76 (0.88–3.54)
Multivariate RR
d (95% CI) 1.16 (0.88–1.54) 1.02 (0.69–1.49) 0.98 (0.61–1.58) 1.10 (0.52–2.35)
aAspirin use was defined as aspirin use two or more times per week. Users consistently reported regular aspirin use (1986; 1986 and 1988; 1986, 1988, and 1990; 1986, 1988,
1990, and 1992); nonusers consistently reported no aspirin use during the specified time periods.
bSeparate proportional hazards models were analysed for each of the four
follow-up periods.
cProportional hazards models adjusted for current age.
dProportional hazards model adjusted for current age, age at started to smoke regularly, and smoking
status (includes dose and time since quitting).
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college, attended graduate school)) was seen among those who
reported aspirin use 3 or more times per week for at least 6
months. Similar reductions in total lung cancer risk were observed
for 5 or more years of aspirin use (OR¼0.68; 95% CI¼0.31–1.51)
(Akhmedkhanov et al, 2002). We used a roughly similar exposure
definition of aspirin use (i.e. aspirin use two or more times per
week), and our findings on duration of aspirin use are in fair
agreement. However, we found no significant association between
aspirin use at baseline and total lung cancer incidence (RR¼1.13;
95% CI¼0.89–1.43, adjusted for current age, age at starting to
smoke regularly, and smoking status (includes dose and time since
quitting)); the risk of total lung cancer associated with consistent
aspirin use for 6 years was slightly inverse (RR¼0.89; 95%
CI¼0.47–1.67) but the results were not statistically significant.
No association was evident between regular aspirin use and
NSCLC in the current study. To date, two case–control studies
have examined the association between regular aspirin use and
NSCLC. In one study, results for NSCLC among women taking
aspirin three or more times per week for at least 6 months
(adjusted OR¼0.39; 95% CI¼0.16–0.96) were stronger that those
when all histological types combined were considered (adjusted
OR¼0.66; 95% CI¼0.34–1.28) (Akhmedkhanov et al, 2002). In
contrast, a second study observed similar significant risk
reductions for NSCLC among men and women who were regular
users of aspirin (adjusted OR¼0.62; 95% CI¼0.45–0.86) and
total lung cancer risk (adjusted OR¼0.57; 95% CI¼0.41–0.78)
(Moysich et al, 2002).
We note a number of potential limitations in the epidemiologic
studies evaluating the role of aspirin and other NSAIDs in lung
cancer risk, including (1) recall bias and selection bias potential in
case–control studies; (2) inefficient control for smoking history;
(3) small numbers of cases; and (4) misclassification due to the
insufficient assessment of long-term aspirin use or lack of detailed
information on aspirin dose. Although we acknowledge the dosage
limitation in the current study, the lack of information on aspirin
dose will result in any potential misclassification of the risk
estimate towards the null. Furthermore, the current study has
strengths regarding the other issues raised. The potential for recall
or selection bias is greatly minimised, if not eliminated, due to the
prospective study design. To minimise confounding by smoking,
smoking habits were modeled to best predict lung cancer. The
relative homogeneity of this population of male health profes-
sionals decreases the likelihood of residual confounding by
smoking or other factor. With repeated measurements of aspirin
use we account for changes in aspirin exposure over time and
reduce the potential for misclassification of aspirin use. The lack of
association observed between aspirin use and lung cancer risk in
the present study might reflect measurement error in aspirin use.
However, using our definition of regular aspirin use, we observed a
markedly decreased risk of colorectal cancer and adenoma in this
same population (Giovannucci et al, 1994), consistent with other
studies. This suggests that we are able to detect important
associations with aspirin use in this study. We were unable to
assess the long-term use of acetaminophen and other NSAIDs due
to the insufficient number of cases among users of these
compounds (range of cases among users¼0–8).
Our findings do not support the hypothesis that regular aspirin
use is associated with a decreased risk of lung cancer. Prevention
of lung cancer should be practiced primarily through smoking
prevention and cessation.
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